TABLE 1.
RECENT POSITIVE ADJUVANT LUNG CANCER TRIALS
| 5-yr Survival (%)
|
||||||
|---|---|---|---|---|---|---|
| Study (reference) | No. | Stage | Chemotherapy Regimen | Control | Chemotherapy arm | p Value |
| IALT (71) | 1,867 | I–IIIA | Cisplatin based Vin/VP/Vb/V | 40 | 45 | < 0.03 |
| Japanese Lung Cancer Research group (72) | 999 | I | Uracil-tegafur | 88 | 85 | 0.71 |
| 90 | 89 (T1) | 0.87 | ||||
| 74 | 85 (T2) | 0.005 | ||||
| NCICTG (73) | 482 | IB/II | Cisplatin/Vin | 54 | 69 | 0.03 |
| ANITA trial (74) | 840 | IB–IIIA | Cisplatin/Vin | 51 | 43 | 0.013 |
| CALGB (53) | 344 | IB | Carboplatin/ paclitaxel | 59 | 71 (4 yr) | 0.028 |
| 60 | 57 (5 yr) | 0.32 | ||||
Definition of abbreviations: ANITA = Adjuvant Navelbine International Trialist Association; CALGB = Cancer and Leukemia Group B; IALT = International Adjuvant Lung Trial; NCICTG = National Cancer Institute of Canada Trials Group; V = vindesine; Vb = vinblastine; Vin = vinorelbine; VP = etosposide.